Exploring miRNA therapies and gut microbiome–enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting

Oct 9, 2024Naunyn-Schmiedeberg's archives of pharmacology

Using microRNA treatments and gut bacteria-boosted CAR-T cells to target brain cancer stem cells

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

A novel therapeutic strategy combining microRNA-based therapies, CAR-T cells, and gut microbiome modulation may target glioblastoma stem cells.

MicroRNA therapies could regulate key signaling pathways involved in glioblastoma progression.
CAR-T cell therapy is being adapted to specifically target glioblastoma stem cell antigens.
The immunosuppressive tumor microenvironment presents challenges for effective treatment.
Research suggests gut dysbiosis may influence systemic inflammation and immune responses in glioblastoma.
Modulating the gut microbiome could enhance the effectiveness of microRNA and CAR-T cell therapies.
This combined approach aims to eradicate primary tumors and prevent recurrence in glioblastoma patients.

AI simplified

Glioblastoma multiforme (GBM) presents a formidable challenge in oncology due to its aggressive nature and resistance to conventional treatments. Recent advancements propose a novel therapeutic strategy combining microRNA-based therapies, chimeric antigen receptor-T (CAR-T) cells, and gut microbiome modulation to target GBM stem cells and transform cancer treatment. MicroRNA therapies show promise in regulating key signalling pathways implicated in GBM progression, offering the potential to disrupt GBM stem cell renewal. CAR-T cell therapy, initially successful in blood cancers, is being adapted to target GBM by genetically engineering T cells to recognise and eliminate GBM stem cell-specific antigens. Despite early successes, challenges like the immunosuppressive tumour microenvironment persist. Additionally, recent research has uncovered a link between the gut microbiome and GBM, suggesting that gut dysbiosis can influence systemic inflammation and immune responses. Novel strategies to modulate the gut microbiome are emerging, enhancing the efficacy of microRNA therapies and CAR-T cell treatments. This combined approach highlights the synergistic potential of these innovative therapies in GBM treatment, aiming to eradicate primary tumours and prevent recurrence, thereby improving patient prognosis and quality of life. Ongoing research and clinical trials are crucial to fully exploit this promising frontier in GBM therapy, offering hope to patients grappling with this devastating disease.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Exploring miRNA therapies and gut microbiome–enhanced CAR-T cells: advancing frontiers in glioblastoma stem cell targeting

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief